All Illumina articles
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
BusinessThe future of ‘next generation’ DNA sequencing
As it gets cheaper and easier to read genetic code, its applications are expanding rapidly
-
Business
Illumina to sue Oxford Nanopore over patent infringement
UK firm’s use of pore proteins in DNA sequencing alleged to contravene two Illumina patents
-
Business
Illumina targets cancer diagnostics
Sequencing will improve tests and speed up clinical trials processes for big pharma partners
-
BusinessRapid DNA sequencing cleared for the clinic
Illumina’s ‘next-generation’ MiSeqDx platform gets US approval
-
Business
Illumina investment push
$450 million deal for privately owned US firm Verinata Health, which makes chromosomal tests
-
FeatureSequencing in the fast lane
Advances in DNA sequencing technology are changing the way scientists look at genomes. Phillip Broadwith gets up to speed with the latest developments